share_log

NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.

Benzinga ·  Sep 12, 2024 12:13
NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment